{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:36:29Z","timestamp":1790436989732,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biliary tract malignancies, in particular cholangiocarcinomas (CCA), are rare tumors that carry a poor prognosis. BRCA2 mutation carriers have an increased risk of developing CCA with a reported relative risk of \u223c5 according to the Breast Cancer Linkage Consortium. In addition to this risk, there are potential therapeutic implications in those harboring somatic and\/or germline (GL) BRCA mutations. Therefore, it is important to define the clinical characteristics of GL\/somatic BRCA1\/2 variants in CCA patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed a multicenter retrospective analysis of CCA patients diagnosed between January 2000 and December 2013 with GL or somatic variants in BRCA1\/2 genes detected by GL mutations testing and\/or by tumor next generation sequencing. Cases were identified from clinical databases at participating institutions. Data including demographics, clinical history, surgical procedures, and systemic chemotherapy or radiation were extracted from patients' records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 18 cases were identified: 5 carriers of GL BRCA1\/2 mutations (4 BRCA2; 1 BRCA1) and 13 harboring somatic variations (7 BRCA1; 6 BRCA2). Mean age at diagnosis was 60, SD\u2009\u00b1\u200910 years (range 36\u201375 years), with male and female prevalence rates of 61.2% and 38.8%, respectively. Stage at diagnosis was I (n\u2009=\u20094), II (n\u2009=\u20093), III (n\u2009=\u20093), and IV (n\u2009=\u20098). Six patients had extrahepatic CCA and the rest intrahepatic CCA. Thirteen patients received platinum-based therapy and four were treated with poly ADP ribose polymerase inhibitors, of whom one experienced sustained disease response with a progression-free survival of 42.6 months. Median overall survival from diagnosis for patients with stage I\/II in this study was 40.3 months (95% confidence interval [CI], 6.73\u2013108.15) and with stages III\/IV was 25 months (95% CI, 15.23\u201340.57).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BRCA-associated CCA is uncommon. This multicenter retrospective study provides a thorough clinical analysis of a BRCA-associated CCA cohort, which can serve as a benchmark for future development and design of expanded analyses and clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2016-0415","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T09:00:59Z","timestamp":1495443659000},"page":"804-810","source":"Crossref","is-referenced-by-count":104,"title":["Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study"],"prefix":"10.1093","volume":"22","author":[{"given":"Talia","family":"Golan","sequence":"first","affiliation":[{"name":"Department of Oncology Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Raitses-Gurevich","sequence":"additional","affiliation":[{"name":"Department of Oncology Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin K.","family":"Kelley","sequence":"additional","affiliation":[{"name":"The University of California, San Francisco Medical Center, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea G.","family":"Bocobo","sequence":"additional","affiliation":[{"name":"The University of California, San Francisco Medical Center, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayelet","family":"Borgida","sequence":"additional","affiliation":[{"name":"Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna T.","family":"Shroff","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spring","family":"Holter","sequence":"additional","affiliation":[{"name":"Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gallinger","sequence":"additional","affiliation":[{"name":"Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ahn","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Aderka","sequence":"additional","affiliation":[{"name":"Department of Oncology Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jain","family":"Apurva","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanois","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitan","family":"Friedman","sequence":"additional","affiliation":[{"name":"Oncogenetics Unit, Institute of Human Genetics, Sheba Medical Center, Tel Hashomer, Israel"},{"name":"Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,9]]},"reference":[{"key":"2021122508115974100_onco12128-bib-0001","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1055\/s-0031-1272839","article-title":"Intrahepatic cholangiocarcinoma: New insights in pathology","volume":"31","author":"Sempoux","year":"2011","journal-title":"Semin Liver Dis"},{"key":"2021122508115974100_onco12128-bib-0002","first-page":"889","article-title":"Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1","volume":"18","author":"Rajagopalan","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"2021122508115974100_onco12128-bib-0003","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.soc.2013.10.001","article-title":"Epidemiology and risk factors of biliary tract and primary liver tumors","volume":"23","author":"Augustine","year":"2014","journal-title":"Surg Oncol Clin N Am"},{"key":"2021122508115974100_onco12128-bib-0004","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.suc.2010.04.011","article-title":"Intrahepatic cholangiocarcinoma","volume":"90","author":"Poultsides","year":"2010","journal-title":"Surg Clin North Am"},{"key":"2021122508115974100_onco12128-bib-0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1499-3872(12)60192-1","article-title":"Modern diagnostic approaches to cholangiocarcinoma","volume":"11","author":"Vasilieva","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2021122508115974100_onco12128-bib-0006","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/PPO.0b013e3181a7467d","article-title":"Intrahepatic cholangiocarcinoma: A worthy challenge","volume":"15","author":"Bartlett","year":"2009","journal-title":"Cancer J"},{"key":"2021122508115974100_onco12128-bib-0007","first-page":"41","article-title":"Toward personalized treatment of advanced biliary tract cancers","volume":"14","author":"Geynisman","year":"2012","journal-title":"Discov Med"},{"key":"2021122508115974100_onco12128-bib-0008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s00595-011-4517-z","article-title":"Surgical outcomes of intrahepatic cholangiocarcinoma","volume":"41","author":"Yamamoto","year":"2011","journal-title":"Surg Today"},{"key":"2021122508115974100_onco12128-bib-0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.critrevonc.2008.09.008","article-title":"Cholangiocarcinoma","volume":"69","author":"Mosconi","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122508115974100_onco12128-bib-0010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"2021122508115974100_onco12128-bib-0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2407-2-10","article-title":"Worldwide trends in mortality from biliary tract malignancies","volume":"2","author":"Patel","year":"2002","journal-title":"BMC Cancer"},{"key":"2021122508115974100_onco12128-bib-0012","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/gut.48.6.816","article-title":"Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968\u20131998","volume":"48","author":"Taylor-Robinson","year":"2001","journal-title":"Gut"},{"key":"2021122508115974100_onco12128-bib-0013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"The Oncologist"},{"key":"2021122508115974100_onco12128-bib-0014","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2021122508115974100_onco12128-bib-0015","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"2021122508115974100_onco12128-bib-0016","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","article-title":"Cancer risks in BRCA2 mutation carriers","volume":"91","author":"Breast Cancer Linkage Consortium","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2021122508115974100_onco12128-bib-0017","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1349-7006.2009.01458.x","article-title":"Epidemiology of cholangiocarcinoma: An update focusing on risk factors","volume":"101","author":"Shin","year":"2010","journal-title":"Cancer Sci"},{"key":"2021122508115974100_onco12128-bib-0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"2021122508115974100_onco12128-bib-0019","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1242\/jcs.114.20.3591","article-title":"Functions of BRCA1 and BRCA2 in the biological response to DNA damage","volume":"114","author":"Venkitaraman","year":"2001","journal-title":"J Cell Sci"},{"key":"2021122508115974100_onco12128-bib-0020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1471-4914(02)02434-6","article-title":"The relationship between the roles of BRCA genes in DNA repair and cancer predisposition","volume":"8","author":"Tutt","year":"2002","journal-title":"Trends Mol Med"},{"key":"2021122508115974100_onco12128-bib-0021","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2021122508115974100_onco12128-bib-0022","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","article-title":"Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer","volume":"70","author":"Tutt","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2021122508115974100_onco12128-bib-0023","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"2021122508115974100_onco12128-bib-0024","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2021122508115974100_onco12128-bib-0025","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2021122508115974100_onco12128-bib-0026","first-page":"505","article-title":"The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women","volume":"60","author":"Abeliovich","year":"1997","journal-title":"Am J Hum Genet"},{"key":"2021122508115974100_onco12128-bib-0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cancergen.2015.11.003","article-title":"The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil","volume":"209","author":"Schayek","year":"2016","journal-title":"Cancer Genet"},{"key":"2021122508115974100_onco12128-bib-0028","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.11002","article-title":"Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS)","author":"Bedard","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122508115974100_onco12128-bib-0029","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2021122508115974100_onco12128-bib-0030","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.bjc.6600840","article-title":"Scottish\/Northern Irish BRCA1\/BRCA2 Consortium. BRCA1 and BRCA2 mutations in Scotland and Northern Ireland","volume":"88","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122508115974100_onco12128-bib-0031","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1038\/sj.onc.1208411","article-title":"Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer","volume":"24","author":"Martin","year":"2005","journal-title":"Oncogene"},{"key":"2021122508115974100_onco12128-bib-0032","article-title":"BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers","volume":"108","author":"Meeks","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2021122508115974100_onco12128-bib-0033","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1093\/hmg\/dds222","article-title":"Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay","volume":"21","author":"Biswas","year":"2012","journal-title":"Hum Mol Genet"},{"key":"2021122508115974100_onco12128-bib-0034","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/ijc.22269","article-title":"Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients","volume":"119","author":"Rashid","year":"2006","journal-title":"Int J Cancer"},{"key":"2021122508115974100_onco12128-bib-0035","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1038\/sj.onc.1205915","article-title":"BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains","volume":"21","author":"Magnard","year":"2002","journal-title":"Oncogene"},{"key":"2021122508115974100_onco12128-bib-0036","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1086\/521032","article-title":"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes","volume":"81","author":"Easton","year":"2007","journal-title":"Am J Hum Genet"},{"key":"2021122508115974100_onco12128-bib-0037","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1158\/0008-5472.CAN-07-1587","article-title":"Functional assays for classification of BRCA2 variants of uncertain significance","volume":"68","author":"Farrugia","year":"2008","journal-title":"Cancer Res"},{"key":"2021122508115974100_onco12128-bib-0038","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1126\/science.297.5588.1837","article-title":"BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure","volume":"297","author":"Yang","year":"2002","journal-title":"Science"},{"key":"2021122508115974100_onco12128-bib-0039","article-title":"SEER Cancer Statistics Review, 1975\u20132013, National Cancer Institute. Bethesda, MD","author":"Howlader","year":"2016","journal-title":"SEER data."},{"key":"2021122508115974100_onco12128-bib-0040","first-page":"519","article-title":"An update on PARP inhibitors for the treatment of cancer","volume":"8","author":"Benafif","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2021122508115974100_onco12128-bib-0041","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122508115974100_onco12128-bib-0042","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"key":"2021122508115974100_onco12128-bib-0043","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/1471-2407-14-528","article-title":"Personalized prostate cancer screening among men with high risk genetic predisposition- Study protocol for a prospective cohort study","volume":"14","author":"Margel","year":"2014","journal-title":"BMC Cancer"},{"key":"2021122508115974100_onco12128-bib-0044","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.clinthera.2016.03.006","article-title":"Genetic testing in pancreatic ductal adenocarcinoma: Implications for prevention and treatment","volume":"38","author":"Peters","year":"2016","journal-title":"Clin Ther"},{"key":"2021122508115974100_onco12128-bib-0045","article-title":"Tumor-specific differences of biliary tract cancers. Presented at: American Society of Clinical Oncology (ASCO) 2015","author":"Thomas","year":"2015","journal-title":"Annual Meeting"},{"key":"2021122508115974100_onco12128-bib-0046","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122508115974100_onco12128-bib-0047","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: Personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Discov"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2016-0415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2016-0415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/804\/41915829\/oncolo_22_7_804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/7\/804\/41915829\/oncolo_22_7_804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:12:37Z","timestamp":1640419957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/7\/804\/6444376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,9]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,5,9]]},"published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2016-0415","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,1]]},"published":{"date-parts":[[2017,5,9]]}}}